Antibody engineering to develop next generation monoclonal antibody therapeutics

Annual Conference on Bioscience

September 12-13, 2016 Berlin, Germany

Maloy Ghosh

Zumutor Biologics, India

Posters & Accepted Abstracts: J Bioeng Biomed Sci

Abstract :

Recombinant therapeutic antibodies constitute the largest share of global Pharmaceutical market; occupy the dominant position of pipeline drugs in disease segments like, oncology and rheumatoid arthritis. Therapeutic antibodies which lack the core fucose oligosaccharide moiety exhibit improved antibody-dependent cellular cytotoxicity (ADCC) response and thereby attain higher efficacy, compared to fucosylated molecules. Genetically engineered mammalian cell line (CHO) platform with impaired fucose biosynthetic pathway were used to express non-fucosylated antibody. Our results suggest complete abrogation of antibody fucosylation and corresponding improvement of ADCC profiles. We have developed Afucosylated AntiHer2 Antibody through this platform which revealed more than 15 folds improvement in ADCC compared to Trastuzumab drug. The fucose knock out CHO expression system will be used to produce multiple next generation antibody therapeutics, especially the Immuno-Onco checkpoint targets. We have developed unique antibody display libraries for discovery and development of new antibody drug molecules. These libraries span over human naive and synthetic molecules developed through rational designing strategies to identify and characterize best in class antibodies. Unique rational designing approach incorporates criteria like thermostability, antigenicity and specificity during antibody library development. Zumutor�s libraries are uniquely positioned, naive antibody gene sequences from Indian sub populations an unexplored resource in this space, integrating rational designing during synthetic library design addressing manufacturability of potential leads, combined phage and yeast display technology that generates lead molecules in both ScFv and Fab formats translation to successful products. This strategy allows discovery of superior antibody molecules with higher affinity and better manufacturability.

Biography :

Email: maloy.ghosh@zumutor.com